Clinical Trial Update: A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC [EARLY_Phase 1]

View source ↗

Summary

A pilot Phase 1 study evaluated atezolizumab (MPDL3280A) in combination with HIGRT for metastatic non-small cell lung cancer. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Non-small Cell Lung Cancer | EARLY_Phase 1 | Status: COMPLETED